New Zealand Data Sheet - Medsafe
New Zealand Data Sheet . In vitro, Levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P. 450
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euEach film-coated tablet contains 250 mg levetiracetam. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
Product, Summary, Characteristics, Summary of product characteristics, Levetiracetam
LEVETIRACETAM 250 MG, 500 MG, 750 MG AND …
www.mhra.gov.ukUKPAR – Levetiracetam 250mg, 500mg, 750mg & 1000 mg Film-Coated Tablets Tablets PL 14017/0228-0231 -2 - LEVETIRACETAM 250 MG, 500 MG…
LEVETIRACETAM Keppra® Vial 100 mg/mL, …
www.segurneo.esLEVETIRACETAM Keppra® Vial 100 mg/mL, solución v.o. 100 mg/mL y comprimidos 250 y 500 mg DOSIS 10 mg/Kg/dosis v.o., i.v. en 15 min a concentración 5 mg/mL Ajustar dosis según necesidad cada 1-2 sem
MATERIAL SAFETY DATA SHEET - Lupin …
www.lupinpharmaceuticals.comMSDS : 033/01 Page 3 of 6 Effective Date : 30/01/2014 6.
Post-Operative Instructions for Patients after …
www.sd-neurosurgeon.comPost-Operative Instructions for Patients after Craniotomy Here are some suggestions for care after a craniotomy (head operation). We realize that it is impossible to anticipate all of the questions or problems that may
Patients, Instructions, Post, Operative, After, Post operative instructions for patients after